ALMB-0166 / CSPC Pharma - LARVOL DELTA

Safety, Tolerability and Efficacy of ALMB-0166 in the Patients with Acute Spine Cord Injury (SCI): A Multicenter, Randomized, Placebo-controlled, Phase I/II Study (AAN 2025) - "At day 56, patients treated with ALMB-0166 had improvement as compared with those given placebo in motor function (scores increased from baseline by 66.0 for 2400 mg and 45.6 for placebo), sensatory function (scores increased by 77.5, 62.7 for 600, 1200 mg and 52.3 for placebo), AIS (2 patients recovered from grade C to grade E for ALMB-0166 and 0 patient recovered to grade E for placebo), and pain (VAS scores decreased by 44.3, 23.7 for 1200, 2400 mg and 20.9 for placebo). Conclusions ALMB-0166 demonstrated great safety profile and improved neurologic recovery in patients with acute SCI."

Clinical • Late-breaking abstract • P1/2 data • Cardiovascular • CNS Disorders • Heart Failure • Hematological Disorders • Inflammation • Pain • Pneumonia • Respiratory Diseases • Thrombosis

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: AlaMab Therapeutics (Shanghai) Inc.

New P1 trial • CNS Disorders • Orthopedics